Atyr Pharma Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Atyr Pharma Inc in the second quarter 2026?
Atyr Pharma Inc recorded a cumulative net loss of $-61 million during 12 months ending in the second quarter 2026, resulting in a negative return on equity (ROE) of -95.75%.

Within the Biotechnology & Pharmaceuticals industry 88 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the first quarter 2026 from 3925 to 4036.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Equity Change	-34.65 %	-22.61 %	-3.64 %	22.88 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-61	-70	-74	-75	-67
Return On Equity (TTM)	-95.75 %	-100.08 %	-99.88 %	-100.37 %	-93.7 %
ATYR's Total Ranking	# 4036	# 3925	# 3151	# 2950	# 2984
Equity (TTM) in Millions	49	58	67	80	75
Seq. Equity Change	-15.79 %	-13.9 %	-15.94 %	7.22 %	-0.28 %
Seq. Net Income Change	-	-	-	-	-

Back to ATYR Management Effectiveness >> ATYR's 5 Years Annual ROE >> Compare ATYR ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 89
Sector	# 612
Overall	# 4036

Return On Equity Statistics
High	Average	Low
371.53 %	-55.92 %	-100.37 %
(Dec 31 2015)		(Sep 30 2025)

News about Atyr Pharma Inc Return on Equity ROE

Shadows and Opportunities The Legal Landscape of aTyr Pharma and Implications for Investors

In recent weeks, the financial theatre surrounding aTyr Pharma, Inc. (NASDAQ: ATYR) has stirred significant concern among its investors, culminating in a class action lawsuit heralded by Pomerantz LLP. As the fiscal tides of the biotechnology sector swell with uncertainty, it becomes imperative for investors who have sustained losses in their investment in aTyr to comprehend the complexities at play and their potential legal recourse.The lawsuit, announced on 17 October 2025, acts as a clarion call a prompt for affected investors to engage with legal counsel to understand the ramifications of their involvement with aTyr Pharma. For those feeling apprehensive or uncertain about the status of their investment, Pomerantz urges individuals to reach out to Danielle Peyton to discuss their circumstances further. As outlined in the announcement, correspondence via email or telephone is warmly encouraged, ensuring that all inquiries are met with the diligence such serious matters demand.

ATYR Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	67	70	90	71	109
Y / Y Equity Change	-3.64 %	-22.81 %	26.91 %	-34.68 %	246.61 %
Net Income in Millions	-74	-64	-50	-45	-34
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	-110.16 %	-91.68 %	-55.71 %	-63.61 %	-30.95 %

Back to ATYR Management Effectiveness >> ATYR's 5 Years Annual ROE >> Compare ATYR ROE to its Competitors

More Return On Equity Ratios
Biotechnology & Pharmaceuticals Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ATYR's' Return on Equity at Yahoo Finance
ATYR's Roe Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ATYR's Competitors
Subscribers only: Roe for Atyr Pharma Inc 's Suppliers
Subscribers only: Return On Equity for ATYR's Customers

Companies with similar Return On Equity at Jun 30 2026, within Healthcare Sector

ROE

Date modified: 2026-08-14T08:40:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.